{
    "case_number": "CAC-UDRP-107335",
    "time_of_filling": "2025-02-19 10:28:13",
    "domain_names": [
        "novartispharmaceuticalscorp.com"
    ],
    "case_administrator": "Olga Dvořáková (Case admin)",
    "complainant": [
        "Novartis AG"
    ],
    "complainant_representative": "Abion GmbH",
    "respondent": [
        "Peter  buyer (Buyer Peter)"
    ],
    "respondent_representative": null,
    "factual_background": "<p>The Complainant is a multinational healthcare company based in Switzerland. Founded in 1996 and nowadays manufactures several well-known drugs which are commercialized worldwide. It has operations over most of the important jurisdictions, including the US market.<\/p>\n<p>&nbsp;No information is known about the Respondent who registered the disputed domain name &lt;novartispharmaceuticalscorp.com&gt; on 19 January 2025. The disputed domain name has been used in connection with any goods or services and resolves to a blank page.<\/p>\n<p style=\"font-weight: 400;\"><span>In view of the above-mentioned, on 21 January, 2025, the Complainant sent a cease and desist letter to the Respondent, via the Registrar&rsquo;s online contact form, and two subsequent reminders on 31 January, 2025, and 5 February, 2025. The Complainant has not received any response.<\/span><\/p>",
    "other_legal_proceedings": "<p>The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>",
    "no_response_filed": "<p style=\"font-weight: 400;\"><span>COMPLAINANT'S CONTENTIONS:<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><strong><em><span>Identical or confusingly similar<\/span><\/em><\/strong><\/p>\n<p style=\"font-weight: 400;\"><strong><em><span>&nbsp;<\/span><\/em><\/strong><\/p>\n<p style=\"font-weight: 400;\"><span>The Complainant argues that the disputed domain name &lt;novartispharmaceuticalscorp.com&gt; and the Complainant's registered trademark NOVARTIS are confusingly similar. <\/span><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>The Complainant argues that its trademark is fully contained within the disputed domain name and points out that the elements in which the signs vary, are descriptive and thus do not alter the overall confusion between the signs. <\/span><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><strong><span>No rights or legitimate interests<\/span><\/strong><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>The Complainant argues that there is no evidence at all that the Respondent is commonly known by the disputed domain name or a name corresponding to the disputed domain name, nor that the Respondent is making a bona fide offering of goods or services or preparing to use the disputed domain name in connection with a bona fide offering of goods and services.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><strong><span>Registered and used in bad faith<\/span><\/strong><\/p>\n<p style=\"font-weight: 400;\"><strong><span>&nbsp;<\/span><\/strong><\/p>\n<p>As far as bad faith registration and use is concerned, the Complainant points out that by incorporating in its second level portion, the Complainant&rsquo;s trademark NOVARTIS in its entirety, followed by the relevant terms &ldquo;pharmaceuticals corporation&rdquo;, a reference to the Complainant&rsquo;s subsidiary &lsquo;Novartis Pharmaceuticals Corporation&rsquo;, the Respondent is making a direct association to the Complainant and its business. Considering this situation and the fact that the Complainant&rsquo;s trademark is well known mark, the Complainant concludes that the Respondent could not be unaware of the Complainant's rights over the name NOVARTIS at the time of the disputed domain name registration.<\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><span>Moreover, the Complainant states that the Respondent is using the registered address of&nbsp; the Complainant&rsquo;s subsidiary &lsquo;Novartis Pharmaceuticals Corporation&rsquo; (59, Route 10, East Hanover, NJ 07936, United States).<\/span><\/p>\n<p>Finally, the website with the disputed domain name is currently inactive and there is no evidence of it having ever been associated with any goods or services. The Complainant underlines that, although the domain name is not being actively used by the Respondent, passive holding may amount to bad faith use under certain circumstances, as in this case.<\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>RESPONDENT'S CONTENTIONS:<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>&nbsp;<\/span><\/p>\n<p style=\"font-weight: 400;\"><span>The Respondent did not respond to the Complaint.<\/span><\/p>",
    "rights": "<p style=\"font-weight: 400;\"><span>The Complainant has, to the satisfaction of the Panel, shown the disputed Domain Name is identical or confusingly similar to trademarks in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/span><\/p>",
    "no_rights_or_legitimate_interests": "<p style=\"font-weight: 400;\"><span>The Complainant has, to the satisfaction of the Panel, shown the Respondent does not have any rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/span><\/p>",
    "bad_faith": "<p style=\"font-weight: 400;\"><span>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/span><\/p>",
    "procedural_factors": "<p>The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>",
    "decision": "Accepted",
    "panelists": [
        "Hana Císlerová"
    ],
    "date_of_panel_decision": "2025-03-23 00:00:00",
    "informal_english_translation": "<p style=\"font-weight: 400;\"><span>The Complainant owns several trademarks consisting either of the word element &ldquo;NOVARTIS&rdquo; alone or where &ldquo;NOVARTIS&rdquo; represents the main distinctive feature. <br \/><\/span><\/p>\n<p style=\"font-weight: 400;\"><span>Some of the most relevant trademarks are as follows:<\/span><span>&nbsp;<\/span><\/p>\n<ul>\n<li><span>International Registration of a word trademark &ldquo;NOVARTIS&rdquo;, No. 663765 in Classes 1;2;3;4;5;7; 8; 9; 10; 14; 16; 17; 20; 22; 28; 29; 30; 31; 32; 40 and <\/span><span>42, <\/span><span>registered on July 1, 1996; <\/span><\/li>\n<li><span>International Registration of a word trademark &ldquo;NOVARTIS&rdquo;, No. 1349878, registered on November 29, 2016, in classes 9, 10, 41, 42, 44 and 45;<\/span><\/li>\n<li><span>The United States trademark NOVARTIS No. 4986124, registered on June 28, 2016, in classes 5, 9, 10, 41, 42 and 44;<\/span><\/li>\n<li><span>The United States trademark NOVARTIS No. 4986124, registered on June 28, 2016;<\/span><\/li>\n<li><span>The United States trademark NOVARTIS No. 6990442, registered on February 28, 2023; and<\/span><\/li>\n<li><span>The EUTM NOVARTIS No. 000304857, registered on 25 June 1999 in classes 1, 5, 9, 10, 29, 30, 31, 32.<\/span><\/li>\n<\/ul>\n<p style=\"font-weight: 400;\"><span>Moreover, the Complainant owns an important domain names portfolio containing the wording NOVARTIS, such as:<\/span><\/p>\n<ul>\n<li><span>&lt;novartis.com&gt; (registered in 1996); and<\/span><\/li>\n<li><span>&lt;novartispharma.com&gt; (registered in 1999).<\/span><\/li>\n<\/ul>",
    "decision_domains": {
        "novartispharmaceuticalscorp.com": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}